Latham & Watkins Corporate Department
|
|
- Tobias White
- 6 years ago
- Views:
Transcription
1 Number 1133 January 27, 2011 Client Alert Latham & Watkins Corporate Department FDA Announces Actions Designed to Improve the 510(k) Premarket Clearance Process Importantly, however, the Agency s identified action items do not provide specific details regarding any changes likely to be imposed over the coming months. On Wednesday, January 19, 2011, the FDA released a plan to improve the current 510(k) program by announcing 25 action items it intends to implement during 2011 to improve the most common path to market for medical devices. FDA identified these actions in its January 19th release after an almost 18-month review of the 510(k) program. Specifically, in August 2010, the Agency formed two working groups, the 510(k) Working Group and the Task Force on the Utilization of Science in Regulatory Decision Making, which were tasked with reviewing and proposing changes to the 510(k) programs to address critical challenges facing the Center and [its] external constituencies. The Agency also said the numerous meetings with the public and industry stakeholders and comments submitted in response to the Agency s proposed recommendations helped to inform the Agency s final recommendations. Importantly, however, the Agency s identified action items do not provide specific details regarding any changes likely to be imposed over the coming months. Instead, the Agency s recommendations signal that the real work of shaping modifications (or clarifications) to the 510(k) program is under way modifications that will be articulated in guidance documents and policies. There will also be opportunities in the coming months to discuss additional areas of potential change to the 510(k) program in FDA s proposed public meetings and topics of continuing evaluation. The Agency developed its action items by categorizing the 55 recommendations made by The Task Force and Working Group into three categories: (i) recommendations with strong support that translated into a specific action item for 2011 implementation; (ii) recommendations with support with a caveat or suggested modification that will be implemented in 2011 with consideration of the caveat or modification and (iii) recommendations with significant concerns that will remain on hold until the Agency receives the Institute of Medicine s Report on the 510(k) Program. Action Item: Wait and See In presenting its recommendations, the Agency explained that the comments it received for some of its proposed recommendations suggested such strong opposition or concern that the Agency is essentially reserving a decision on final disposition of those recommendations for now. Because of the significant concerns raised by industry stakeholders, FDA stated that it intended to wait and see if the Institute of Medicine (IOM) addressed some or all of the most Latham & Watkins operates worldwide as a limited liability partnership organized under the laws of the State of Delaware (USA) with affiliated limited liability partnerships conducting the practice in the United Kingdom, France, Italy and Singapore and an affiliated partnership conducting the practice in Hong Kong and Japan. Latham & Watkins practices in Saudi Arabia in association with the Law Office of Mohammed Al-Sheikh. Under New York s Code of Professional Responsibility, portions of this communication contain attorney advertising. Prior results do not guarantee a similar outcome. Results depend upon a variety of factors unique to each representation. Please direct all inquiries regarding our conduct under New York s Disciplinary Rules to Latham & Watkins LLP, 885 Third Avenue, New York, NY , Phone: Copyright 2011 Latham & Watkins. All Rights Reserved.
2 controversial of the recommendations. Specifically, IOM is conducting an independent evaluation of the 510(k) program and is expected to issue its report in mid Some of these wait and see recommendations include: Consolidation of the terms indications for use and intended use into a single intended use term Issuing a regulation on FDA rescission authority Expanding FDA s authority to consider off-label use when determining the intended use of a device Issuing guidance on removing a device from consideration as a predicate Requiring manufacturers to keep one unit of a device available Issuing guidance to create a Class IIb classification Seeking additional authority to condition clearance of certain devices on required postmarketing surveillance studies During a press conference announcing its action items, the Agency indicated that it had no plans to formally discuss the IOM s review of the 510(k) program or these recommendations specifically. Although it is likely that the IOM report will address some, if not all, of these topics at least indirectly, there is no guarantee that it will do so. Moreover, industry stakeholders will need to monitor FDA s reaction to the IOM report and what action, if any, the Agency signals it may take after the IOM report is released. Action Item: Draft Guidance Among the key action items the Agency intends to implement and the anticipated dates of completion are a series of draft guidance documents which will be intended to: Streamline the de novo review process for certain lower-risk medical devices Clarify when the Agency will require the submission of clinical data to support a premarket submission Clarify when changes to a cleared medical device warrant a new 510(k) and which modifications would be eligible for a Special 510(k) (June 15, 2011) Clarify when the Agency will require the submission of photographs or schematics for internal FDA use only during the 510(k) review process Clarify the criteria for identifying different questions of safety and effectiveness and technological changes that generally raise such questions Clarify the appropriate use of multiple predicates to support a premarket submission Clarify the characteristics that should be included in the concept of intended use Resolve discrepancies between the 510(k) flowchart and the FDCA Improve the quality and performance of clinical trials (July 31, 2011) Clarify the appropriate use of consensus standards (October 31, 2011) Clarify the process for appealing CDRH decisions (October 31, 2011) Expand available guidance on pre- IDE meetings and enhance the quality of pre-submission interactions between the industry and CDRH staff (November 30, 2011) Although guidance documents do not create binding obligations on the FDA or industry, they are helpful because the represent the Agency s current thinking on a matter. Moreover, the issuance of a draft guidance signals an opportunity for the Agency to provide comments and feedback to the Agency before the Guidance document is finalized. As a result, it will be important to monitor the FDA s progress in issuing these draft guidance documents and providing 2 Number 1133 January 27, 2011
3 the Agency with meaningful feedback in order to assist the Agency create meaningful Guidance that will help to achieve greater transparency and predictability in the Agency s processes while fostering innovation in medical device technology. Action Item: Draft and Publish FDA Policies The Agency also intends to implement several internal or administrative matters that are intended to further support innovation, improve transparency and offer predictability in the review process. Included in these changes is the Agency s plan to establish a Center Science Council within CDRH that would be tasked with oversight of the development of a business process and procedure for determining and implementing an appropriate response to new scientific information. The Center Science Council would also be tasked with auditing FDA s 510(k) decisions to assess adequacy, accuracy and consistency. The FDA intends to develop and post the Council s charter by March 31, The FDA has also stated that the Council s first audit of 510(k) review decisions would be posted to FDA s website by June 15, Significantly, FDA s action items for the Council do not provide an intended timeframe for the Council developing an SOP for determining and implementing FDA s response to new scientific information. This is one area, in particular, where the Council s charter and additional information from FDA in the coming months regarding the Council s tasks will warrant additional attention. FDA s intended action items also include the development and publication of several FDA internal policies and procedures in order to foster transparency and predictability. For example, the Agency intends to provide public access via FDA s website to FDA s policies for staff interactions and utilization of external experts by September 15, The Agency also intends to publish a policy on Notice to Industry Letters which will inform stakeholders when CDRH has changed its regulatory expectations on the basis of new scientific information. The SOP is intended to provide industry with insight on FDA s process for issuing a Notice to Industry Letter and is designed to help eliminate some of the confusion regarding changes to FDA s review requirements on a case-by-case basis. Another administrative matter that the Agency is working on is developing a network of external experts to appropriately and efficiently leverage external scientific expertise, including assessing best-practices and developing SOPs for staff engagement with external experts. FDA intends to develop and post these SOPs on its website by September 15, Action Item: Evaluate and Discuss The Agency s intended action items include a number of items in which the Agency intends to continue seeking information and comments which, presumably, will inform future program modifications. For example, FDA is sensitive to challenges and inconsistencies in IDE decision making at the Agency. In order to improve the IDE process, FDA intends to characterize the root causes of these challenges and to identify trends in IDE decision-making. Concurrently, the Agency has identified that it intends to assess, characterize, and mitigate these challenges through an IDE program assessment. The Agency intends to complete this assessment by June 30, FDA also intends to complete specific action items for improving the collection and analysis of postmarket information. By June 30, 2011, FDA has proposed to have determined the system requirements and selected the platform for creating a new adverse 3 Number 1133 January 27, 2011
4 event database. The Agency hopes with this database to enhance its evidence synthesis and quantitative decision making regarding postmarket information. In its action items, the Agency has also announced a public meeting on April 7-8, 2011 to discuss specific recommendations that it believes require additional feedback from industry stakeholders in order to effectively implement. Specifically, the Agency intends to discuss at the public meeting when and how it should make device photographs available in a public database in order to provide additional information about regulated products to the public while balancing the need to protect proprietary information. The second topic identified for the April public meeting is a discussion of FDA s intent to develop an on-line labeling repository. Action Item: Issue Regulations FDA identifies three categories of proposed regulations that it intends to issue in The first regulation pertains to FDA s implementation of a Unique Device Identification (UDI) System. A UDI System has been on-going and garnered much attention and industry discussion. Obviously, FDA s proposed regulations will require much thought and comment by industry stakeholders to assist the Agency in implementing this System in a manner that is not overly-burdensome, protects proprietary information, and is costeffective. The Agency intends to promulgate its proposed UDI System regulations by June 30, The Agency is also working to develop and issue proposed regulations on ownership transfers of 510(k) clearances and the statutory listing requirements for the submission of labeling. FDA intends to issue these regulations by December 31, * * * Ultimately, the Agency s released action items signal that there will be a continuing need to work with the Agency during the development, dissemination, and finalization of its anticipated Guidance Documents, policies, and regulations. There will also be a continuing need to work with the Agency regarding its continuing evaluation of the 510(k) program as the Agency contemplates additional modifications and clarifications. We will continue to monitor the Agency s progress on its announced action items. Please do not hesitate to contact us if you would like additional information regarding any of the FDA s intended action items or its continuing review of the 510(k) program and the implications for your medical devices. If you have any questions about this Client Alert, please contact one of the authors listed below or the Latham attorney with whom you normally consult: John R. Manthei john.manthei@lw.com J. Benneville (Ben) Haas ben.haas@lw.com Rebecca N. Brandt rebecca.brandt@lw.com Houston 4 Number 1133 January 27, 2011
5 Client Alert is published by Latham & Watkins as a news reporting service to clients and other friends. The information contained in this publication should not be construed as legal advice. Should further analysis or explanation of the subject matter be required, please contact the attorney with whom you normally consult. A complete list of our Client Alerts can be found on our website at If you wish to update your contact details or customize the information you receive from Latham & Watkins, please visit to subscribe to our global client mailings program. Abu Dhabi Barcelona Beijing Brussels Chicago Doha Dubai Frankfurt Hamburg Hong Kong Houston London Los Angeles Madrid Milan Moscow Munich New Jersey New York Orange County Paris Riyadh* Rome San Diego San Francisco Shanghai Silicon Valley Singapore Tokyo * In association with the Law Office of Mohammed A. Al-Sheikh 5 Number 1133 January 27, 2011
PLAN OF ACTION FOR IMPLEMENTATION OF 510(K) AND SCIENCE RECOMMENDATIONS
PLAN OF ACTION FOR IMPLEMENTATION OF 510(K) AND SCIENCE RECOMMENDATIONS In August 2010, the Food and Drug Administration s Center for Devices and Radiological Health (CDRH or the Center) released for public
More informationClient Alert. European Commission Proposes Overhaul of EU Clinical Trials Legislation
Number 1374 July 30, 2012 Client Alert Latham & Watkins Corporate Department European Commission Proposes Overhaul of EU Clinical Trials Legislation Only time will tell whether the Commission will achieve
More informationFSVP and VQIP Statutory Requirements GMA Science Forum
FSVP and VQIP Statutory Requirements GMA Science Forum Maile Gradison Hermida Elizabeth Barr Fawell April 5, 2012 FSMA Overview New controls over imported food are a key component of FSMA Volume of imports
More informationWestfield Fashion Square Restaurant Renovation Project Council File ; CPC VZC; ENV ND
355 South Grand Avenue Los Angeles, California 90071-1560 Tel: +1.213.485.1234 Fax: +1.213.891.8763 www.lw.com December 12, 2016 BY HAND DELIVERY AND EMAIL Councilmember Jose Huizar, Chair Councilmember
More informationLatham & Watkins Energy Practice Group Climate Change Practice Group Cleantech Practice Group Project Development and Finance Practice Group
Number 814 February 18, 2009 Client Alert Latham & Watkins Energy Practice Group Climate Change Practice Group Cleantech Practice Group Project Development and Finance Practice Group Clean Energy and Electric
More informationInformation for charities
Global charity partnership 2014-2016 Information for charities Allen & Overy 2014 A&O s Global Charity Partnership 2014 2016: Information for charities Criteria Allen & Overy staff and partners have voted
More informationMDUFA Performance Goals and Procedures Process Improvements Pre-Submissions Submission Acceptance Criteria Interactive Review
Page 1 MDUFA Performance Goals and Procedures... 3 I. Process Improvements... 3 A. Pre-Submissions... 3 B. Submission Acceptance Criteria... 4 C. Interactive Review... 5 D. Guidance Document Development...
More informationInformation for charities
Global Charity Partnership 2016-2018 Information for charities Allen & Overy 2016 Allen & Overy s Global Charity Partnership 2016 2018 Criteria and key details Allen & Overy s Global Charity Partnership
More informationGlobal REACH legal services
Global REACH legal services www.allenovery.com 2 Global REACH legal services REACH: How can Allen & Overy assist you? REACH is one of the most ambitious pieces of legislation to come out of Europe to date
More informationNovember 7, Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, Room 1061 Rockville, MD 20852
1300 North 17 th Street Suite 1752 Arlington, Virginia 22209 Tel: 703.841.3200 Fax: 703.841.3392 www.medicalimaging.org November 7, 2011 Division of Dockets Management (HFA-305) Food and Drug Administration
More informationLatham & Watkins Corporate Department
Number 448 April 12, 2005 Client Alert Latham & Watkins Corporate Department Unbundling obligations will be lifted over time as competitive carriers deploy their own networks, but the most significant
More informationHealth Care Alert. Proposed Rules Seek to Offer Hospitals Clarity and Flexibility. Physician Supervision of Outpatient Services.
July 23, 2009 Authors: Mary Beth F. Johnston marybeth.johnston@klgates.com +1.919.466.1181 Kelly D. Furr kelly.furr@klgates.com +1.919.466.1240 Katharine L. Schaeffer kathy.schaeffer@klgates.com +1.919.466.1114
More informationHealth Care Alert. CMS Update: New Rules for Home Health Agencies Undergoing Ownership Changes. Further Update (December 17, 2010)
February 2010 Authors: Richard P. Church richard.church@klgates.com 919.466.1187 Darlene S. Davis darlene.davis@klgates.com 919.466.1119 Virginia E. Worthy jenny.worthy@klgates.com 704.331.7508 K&L Gates
More informationHealth Care Alert. CMS Update: New Rules for Home Health Agencies Undergoing Ownership Changes. Further Update (July 23, 2010)
February 2010 Authors: Richard P. Church richard.church@klgates.com 919.466.1187 Darlene S. Davis darlene.davis@klgates.com 919.466.1119 Virginia E. Worthy jenny.worthy@klgates.com 704.331.7508 K&L Gates
More informationHealth Law Practice. Pillsbury Winthrop Shaw Pittman LLP pillsburylaw.com
Health Law Practice Pillsbury Winthrop Shaw Pittman LLP pillsburylaw.com Health Law Practice 2 Pillsbury Winthrop Shaw Pittman LLP Transforming your vision into reality requires foresight that s 20/20.
More information510(k) Clinical Data Requirements: Current Status and Considerations for Clinical Studies
510(k) Clinical Data Requirements: Current Status and Considerations for Clinical Studies Sandra Maddock, RN, BSN, CCRA IMARC Research, Inc. Introduction In an effort to promote innovation while protecting
More informationContains Nonbinding Recommendations. Draft Not for Implementation
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 Public Notification of Emerging Postmarket Medical Device Signals ( Emerging Signals ) Draft Guidance for Industry
More informationSeptember 16 th, Dockets Management Branch (HFA-305) Food and Drug Administration 5630 Fishers Lane, Rm Rockville, MD 20852
September 16 th, 2013 Dockets Management Branch (HFA-305) Food and Drug Administration 5630 Fishers Lane, Rm. 1061 Rockville, MD 20852 Re: Docket No. FDA-2013-N-0502: Standardizing and Evaluating Risk
More informationNew federal requirements for posting of clinical trials information
in the news Health Care October 2016 New Clinical Trial Rule Alters Reporting Requirements In this Issue: Introduction... 1 Types of Clinical Trials Subject to the Final Rule... 2 The Responsible Party
More informationInteractive Review for Medical Device Submissions: 510(k)s, Original PMAs, PMA Supplements, Original BLAs, and BLA Supplements
Guidance for Industry and FDA Staff Interactive Review for Medical Device Submissions: 510(k)s, Original PMAs, PMA Supplements, Original BLAs, and BLA Supplements Document Issued on: February 28, 2008
More informationRe: Docket No. FDA 2013-N-0500 Proposed Rule: Supplemental Applications Proposing Labeling Changes for Approved Drugs and Biological Products
March 13, 2014 BY ELECTRONIC DELIVERY Dockets Management Branch (HFA-305) Food and Drug Administration 5630 Fishers Lane, Rm. 1061 Rockville, MD 20852 Re: Docket No. FDA 2013-N-0500 Proposed Rule: Supplemental
More informationFDA s Office of Regulatory Affairs: Violation Trends & Medical Device Update
FDA s Office of Regulatory Affairs: Violation Trends & Medical Device Update Ginger M. Sykes Supervisory Consumer Safety Officer Salt Lake City Resident Post Office of Regulatory Affairs U.S. Food and
More informationHarris & Associates / IIC Partners
Harris & Associates / IIC Partners Local focus, global reach, world-class results Harris & Associates / IIC Partners 4236 Tuller Road Dublin, OH 43017 Tel: 614.798.8500 Fax: 614.798.8588 IIC Partners Who
More informationMay 8, Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, Room 1061 Rockville, MD
701 Pennsylvania Avenue, NW Suite 800 Washington, D.C. 20004 2654 Tel: 202 783 8700 Fax: 202 783 8750 www.advamed.org May 8, 2014 Division of Dockets Management (HFA-305) Food and Drug Administration 5630
More informationReceived an RTA Deficiency List or AI Letter? Now What?
Received an RTA Deficiency List or AI Letter? Now What? Dealing with Unexpected Issues/Questions during the Submission Review Process Navigating Submission Challenges to reduce time & risk September 26,
More informationRegTech in Asia Opportunities & Challenges
Regtech World Tour: Asian Chapter Ho Chi Minh City 23 Nov 2017 RegTech in Asia Opportunities & Challenges Manfred K. Otto Duane Morris Vietnam LLC 2017 Duane Morris LLP. All Rights Reserved. Duane Morris
More informationExploring Opportunities in Emerging Markets
Exploring Opportunities in Emerging Markets Enterprise Ireland - Supporting companies access procurement opportunities in IFI June 19 2012 Evelyn Smith Public Procurement Enterprise Ireland An Agency of
More informationStandards and Medical Device Regulation Roundtable. Seoul South Korea. 21 October ASTM International
Standards and Medical Device Regulation Roundtable Seoul South Korea 21 October 2014 FDA s Use of Voluntary Consensus Standards Scott Colburn, Director CDRH Standards Program Office of the Center Director,
More informationGuidance for Industry and Food and Drug Administration Staff
Requests for Feedback on Medical Device Submissions: The Pre-Submission Program and Meetings with Food and Drug Administration Staff Guidance for Industry and Food and Drug Administration Staff Document
More informationJuly 7, Dear Mr. Patel:
Bakul Patel Senior Policy Advisor United States Food and Drug Administration Center for Devices and Radiological Health Division of Dockets Management (HFA-305) 5630 Fishers Lane, Rm. 1061 Rockville, MD
More informationFaster, More Efficient Innovation through Better Evidence on Real-World Safety and Effectiveness
Faster, More Efficient Innovation through Better Evidence on Real-World Safety and Effectiveness April 28, 2015 l The Brookings Institution Authors Mark B. McClellan, Senior Fellow and Director of the
More informationOutsourcing highlights
Outsourcing highlights 2017 2 Outsourcing highlights 2017 Choosing Allen & Overy A global market leader Our international outsourcing practice has established itself as a market leader, advising on the
More informationUK WORKPLACE SURVEY 2016
UK WORKPLACE SURVEY 2016 UK Workplace Haves & Have-Nots Can we make UK office environments work better for everyone? WHAT WE DID We surveyed a panel-based sample of over 1,200 UK office workers in 11 industries
More informationFDA Reauthorization Act of 2017 (FDARA)
FDA Reauthorization Act of 2017 (FDARA) April 4, 2018 PRESENTED BY: Jessica Ringel Counsel FDA & Life Sciences Practice Group King & Spalding LLP (202) 626-9259 jringel@kslaw.com FDA Reauthorization Act
More informationMedical Devices and Device-Led Combination Products; Voluntary Malfunction Summary
This document is scheduled to be published in the Federal Register on 08/17/2018 and available online at https://federalregister.gov/d/2018-17770, and on govinfo.gov 4164-01-P DEPARTMENT OF HEALTH AND
More informationCMS equip: Helping Start-ups Scale
CMS equip: Helping Start-ups Scale CMS equip: helping start-ups scale Starting, and building, a successful business takes a good idea, energy and determination plus the right opportunities and the right
More informationShared Ownership Hydro Projects
Shared Ownership Hydro Projects British Hydro Power Association Annual Conference Anna Cameron Associate, Cameron McKenna A top 10 global law firm and the largest in Europe 59 offices, approximately 4,000
More informationOECD Webinar on alternatives to long chain PFCs Co-organized with the Stockholm Convention Secretariat 18 April 2011
OECD Webinar on alternatives to long chain PFCs Co-organized with the Stockholm Convention Secretariat 18 April 2011 Information note Objective: To provide updates on activities related to alternatives
More informationDraft PPP Regulations
Legal Update Infrastructure PPP/PFI Vietnam 3 September 2010 Draft PPP Regulations Vietnam has an urgent need to upgrade and develop its infrastructure. However, having attained middle income status, the
More informationDDTC Issues Overly Expansive Interpretation of the ITAR for Defense Services (and Presumably Technical Data)
DDTC Issues Overly Expansive Interpretation of the ITAR for Defense Services (and Presumably Technical Data) Summary Christopher B. Stagg Attorney, Stagg P.C. Client Alert No. 14-12-02 December 8, 2014
More informationAN OVERVIEW OF CLINICAL STUDY TASKS AND ACTIVITIES
1 AN OVERVIEW OF CLINICAL STUDY TASKS AND ACTIVITIES Key Clinical Study Tasks and Activities 2 Discussion of Key Tasks and Activities 3 Development of the Clinical Protocol and Study Materials 3 Qualification
More informationof Study Abroad Programs Operated by Overseas Universities.
Go Global Scholarships First Call for the 2018 Short (3 months-1 year) Study Abroad Scholarships First Call for the 2018 S-Short (less than 3 months) Study Abroad Scholarships Information for Applicants
More informationHealth Care Alert. Health Care Reform Client Alert Series
August 2010 Authors: Paul W. Shaw paul.shaw@klgates.com +1.617.261.3111 Stephanie D. Wall stephanie.wall@klgates.com +1.412.355.8364 K&L Gates includes lawyers practicing out of 36 offices located in North
More informationPostmarketing Drug Safety and Inspection Readiness
Postmarketing Drug Safety and Inspection Readiness June 19, 2018 Center for Drug Evaluation and Research (CDER) Small Business and Industry Assistance (SBIA) Webinar United States Food and Drug Administration
More informationTopic: CAP s Legislative Proposal for Laboratory-Developed Tests (LDT) Date: September 14, 2015
Topic: CAP s Legislative Proposal for Laboratory-Developed Tests (LDT) Date: September 14, 2015 1. What are the CAP s views on the regulatory oversight of laboratory-developed tests (LDTs)? 2. How are
More informationRegistry of Patient Registries (RoPR) Policies and Procedures
Registry of Patient Registries (RoPR) Policies and Procedures Version 4.0 Task Order No. 7 Contract No. HHSA290200500351 Prepared by: DEcIDE Center Draft Submitted September 2, 2011 This information is
More informationSolutions for GCP Compliance Challenges. September 23, 2015 Northwestern University IRB Brown Bag Session
Solutions for GCP Compliance Challenges September 23, 2015 Northwestern University IRB Brown Bag Session PAMELA MASON, MPH Vice President, Mason Professional Services, LLC Adjunct Faculty, Northwestern
More informationSolutions for GCP Compliance Challenges
Solutions for GCP Compliance Challenges September 23, 2015 Northwestern University IRB Brown Bag Session PAMELA MASON, MPH Vice President, Mason Professional Services, LLC Adjunct Faculty, Northwestern
More informationPre-Submissions and Meetings with FDA Staff
Pre-Submissions and Meetings with FDA Staff Soma Kalb, PhD Acting Director, IDE Program Office of Device Evaluation Elizabeth Hillebrenner, MSE Policy Analyst Office of In Vitro Diagnostics & Radiological
More informationCluster Munitions Legislation in the Netherlands
Cluster Munitions Legislation in the Netherlands Terence Berkleef Responsible Investment Manager, Sustainalytics Terence.Berkleef@sustainalytics.com UKSIF, 15 May 2013 Agenda 1. Introduction 2. Overview
More informationMEMORANDUM. From: Gary Jay Kushner Brian D. Eyink. Date: August 14, FSIS Releases Final Poultry Slaughter Rule
Hogan Lovells US LLP Columbia Square 555 Thirteenth Street, NW Washington, DC 20004 T +1 202 637 5600 F +1 202 637 5910 www.hoganlovells.com MEMORANDUM From: Gary Jay Kushner Brian D. Eyink Date: August
More informationAlumni Network. Connecting alumni, partners and employees
Alumni Network Connecting alumni, partners and employees 2 Connecting People at A&O and beyond Our alumni explain why the A&O Alumni Network is useful to them Since 2005, A&O has been committed to keeping
More informationIEEE ISCAS Bid Packet Requirements and Timeline
IEEE ISCAS Bid Packet Requirements and Timeline The venue for the future International Symposium for Circuits and Systems (ISCAS) four (4) years ahead is selected by the ISCAS Steering Committee, normally
More informationU.S. Nuclear Export Controls and Proposed Changes to the Part 810 Regulations
U.S. Nuclear Export Controls and Proposed Changes to the Part 810 Regulations DC ANS Speaker Series Ajay Kuntamukkala & Darshak Dholakia Hogan Lovells US LLP February 7, 2013 Agenda Overview of Nuclear
More informationGerman FinTechs and traditional banks: Friend or Foe?
German FinTechs and traditional banks: Friend or Foe? FinTechs Definition and categories Non-bank, technology-driven providers of financial services, built on digitalised, web- and data based processes
More informationOPDP Update on Oversight of Prescription Drug Promotion
OPDP Update on Oversight of Prescription Drug Promotion Thomas Abrams Director Office of Prescription Drug Promotion Food and Drug Administration October 20, 2016 Topics Policy and Guidance Development
More informationEnterprise Ireland Overview Irish State Indigenous Industry Development Agency
Enterprise Ireland Overview Irish State Indigenous Industry Development Agency What we do Work with 5,000 Irish owned businesses across all sectors of manufacturing and internationally created services
More informationA Competitiveness Policy for the Medical Technology Industry: Six Policy Proposals to Sustain American Leadership
A Competitiveness Policy for the Medical Technology Industry: Six Policy Proposals to Sustain American Leadership 1. Innovation in the life sciences must be a government priority. Since the ability of
More informationReal-World Evidence: A CDRH Perspective
Real-World Evidence: A CDRH Perspective Karen Ulisney, MSN, CRNP Policy Analyst, Clinical Trials Program Office of Device Evaluation CDRH, FDA Case for Quality Forum July 20, 2017 Patients are at the Heart
More informationSmart cities in Europe Can public procurement be used as leverage to drive smart city solutions?
Smart cities in Europe Can public procurement be used as leverage to drive smart city solutions? 9 3 Smart cities in Europe The future of the built environment Part of the Smart cities in Europe series
More informationWhat Will Be Covered:
A View From New York: Compliance Mandates You May See in Your State Health Care Compliance Association (HCCA) April 23, 2013 National Harbor, Maryland Carol Booth, Compliance Specialist NYS Office of Medicaid
More informationPresentation by Julie Sinnamon, CEO Enterprise Ireland. 22 nd November 2016
Presentation by Julie Sinnamon, CEO Enterprise Ireland 22 nd November 2016 Enterprise Ireland Work with 5,000 Irish owned businesses across all sectors with export potential and regions To help them to
More informationFINAL STATUS DOCUMENT
GHTF/SG2/N68R3: 2005 FINAL STATUS DOCUMENT Global Harmonization Task Force Title: Summary of Current Requirements for Where to Send Adverse Event Reports. Authoring Group: GHTF Study Group 2 Endorsed by:
More informationITS Maryland 2013 Annual Conference October 8, 2013
Leveraging Maryland's Public Private Partnership (P3) Legislation for Investment in Transportation Technology ITS Maryland 2013 Annual Conference October 8, 2013 Towards a More Comprehensive P3 Approach
More informationDefense Logistics Agency INSTRUCTION
Defense Logistics Agency INSTRUCTION DLAI 4208 Effective February 6, 2013 SUBJECT: Financial Liability for Property and Equipment (P&E) that is Lost, Damaged, Destroyed, or Stolen (LDDS) References: Refer
More informationThe Low Carbon Investment Landscape in C40 Cities. An analysis of the sustainable infrastructure projects currently in development across C40 cities
The Low Carbon Investment Landscape in C40 Cities An analysis of the sustainable infrastructure projects currently in development across C40 cities Executive Summary Over the past few years, C40 cities
More informationTake a Course of Action.
Take a Course of Action. When you choose RAPS Online University, you ll be on track to expand your regulatory knowledge and advance your career. Our comprehensive learning provides an immersive experience
More informationDRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Document issued on: August 5, 2008
Draft Guidance for HDE Holders, Institutional Review Boards (IRBs), Clinical Investigators, and FDA Staff Humanitarian Device Exemption (HDE) Regulation: Questions and Answers DRAFT GUIDANCE This guidance
More informationFDA Guidance Hot Topics: Pre-Submission Guidance Review AMDM Focus Meeting October 25, Elizabeth Hillebrenner, MSE OIR/CDRH/FDA
FDA Guidance Hot Topics: Pre-Submission Guidance Review AMDM Focus Meeting October 25, 2013 Elizabeth Hillebrenner, MSE OIR/CDRH/FDA Updates to Guidance: Draft Final Broaden scope to address all types
More informationBiomedical IRB MS #
Department for Human Research Protections Institutional Review Boards Biomedical IRB MS # 1035 419-383-6796 IRB.Biomed@utoledo.edu Social, Behavioral and Educational IRB MS # 944 419-530-6167 IRB.SBE@utoledo.edu
More informationEstablishment of the FDA Office of Patient Affairs
Establishment of the FDA Office of Patient Affairs Policy Proposal: With the advent of new and innovative patient engagement programs within the Food and Drug Administration (FDA), a growing need for greater
More informationChina s Ongoing Healthcare Reform and Compliance Changes to the Pharma Industry
BEIJING BRUSSELS CHICAGO DALLAS FRANKFURT GENEVA HONG KONG LONDON LOS ANGELES NEW YORK SAN FRANCISCO SHANGHAI SINGAPORE SYDNEY TOKYO WASHINGTON D.C. 北京布鲁赛尔芝加哥达拉斯法兰克福日内瓦香港伦敦洛杉矶纽约旧金山上海新加坡悉尼东京华盛顿 China s
More informationEPA s Integrated Risk Information System Assessment Development Procedures
1 1 1 0 1 0 1 EPA s Integrated Risk Information System Assessment Development Procedures Introduction: The Integrated Risk Information System (IRIS) is a U. S. Environmental Protection Agency (EPA) database
More informationGAO MEDICAL DEVICES. Status of FDA s Program for Inspections by Accredited Organizations. Report to Congressional Committees
GAO United States Government Accountability Office Report to Congressional Committees January 2007 MEDICAL DEVICES Status of FDA s Program for Inspections by Accredited Organizations GAO-07-157 Accountability
More informationCase 1:17-cv AT-DCF Document 54 Filed 01/16/18 Page 1 of 5
Case 1:17-cv-07994-AT-DCF Document 54 Filed 01/16/18 Page 1 of 5 51 LOUISIANA AVENUE, N.W. WASHINGTON, D.C. 20001.2113 TELEPHONE: +1.202.879.3939 FACSIMILE: +1.202.626.1700 January 16, 2018 VIA ECF Hon.
More informationASIA WORKPLACE SURVEY 2016
ASIA WORKPLACE SURVEY 2016 Forging a Uniquely Asian Workplace ACE WORKPL HIGH-PERFORMANCE A OF DNA 3.4 Can the Asian workplace embrace experimentation and balance to create a distinct identity? EFFECTIVE
More informationSmartrev Cybersec. Cybersecurity Innovation Partners. RESEARCH - Understanding key metrics impacting cybersecurity start-ups growth globally
Smartrev Cybersec Cybersecurity Innovation Partners RESEARCH - Understanding key metrics impacting cybersecurity start-ups growth globally Jose Monteagudo CEO Madrid, Tel Aviv, NY, London, Singapore February
More informationNUCLEAR REGULATORY UPDATE
NUCLEAR REGULATORY UPDATE Paul M. Bessette Grant W. Eskelsen Ryan K. Lighty July 25, 2017 2015 Morgan, Lewis & Bockius LLP AGENDA 1 2 3 4 5 6 7 Decommissioning Spotlight Enforcement Trends Severe Accident
More information2015 Annual FDA Medical Device Quality System Data. Inspections, FDA Form 483 Observations, and Warning Letter Citations
2015 Annual FDA Medical Device Quality System Data Inspections, FDA Form 483 Observations, and Warning Letter Citations Why is FDA making these data available? In support of the FDA s Transparency and
More informationBetter Medical Device Data Yield Improved Care The benefits of a national evaluation system
A fact sheet from Aug 2016 Better Medical Device Data Yield Improved Care The benefits of a national evaluation system Overview The current system for evaluating implanted medical devices provides inadequate
More informationMassachusetts Peer Review Protections: How Do They Apply? May 12, a.m. 12 p.m.
Massachusetts Peer Review Protections: How Do They Apply? May 12, 2017 10 a.m. 12 p.m. Michael R. Callahan Katten Muchin Rosenman Chicago +1.312.902.5634 michael.callahan@kattenlaw.com 126471698 Hypothetical
More informationEurope, Middle East and Africa
Business Overview Europe, Middle East and Africa Mizuho Bank Teiji Teramoto Managing Executive Officer Head of Europe, Middle East and Africa and transaction business where we are expanding our capabilities
More informationIntel Involved Matching Grant Program Procedure for Eligibility Application
Procedure for Eligibility Application In order for the to consider your organization eligible to receive volunteer matching grants from the program, we ask that you complete and return the enclosed Matching
More informationFDA Vision for Innovative Surveillance of Orthopedic Implants
FDA Vision for Innovative Surveillance of Orthopedic Implants Danica Marinac-Dabic, MD, PhD Director, CDRH Division of Epidemiology Head, FDA ICOR Initiative Total and Resurfacing Hip Systems: Post-Approval
More informationINTELLIGENCE COMMUNITY DIRECTIVE NUMBER 501
INTELLIGENCE COMMUNITY DIRECTIVE NUMBER 501 DISCOVERY AND DISSEMINATION OR RETRIEVAL OF INFORMATION WITHIN THE INTELLIGENCE COMMUNITY (EFFECTIVE: 21 JANUARY 2009) A. AUTHORITY: The National Security Act
More informationLONDON AND THE UK A GREAT OPPORTUNITY FOR CHINESE COMPANIES AND INVESTORS
LONDON AND THE UK A GREAT OPPORTUNITY FOR CHINESE COMPANIES AND INVESTORS 3 WELCOME TO LONDON AND THE UK London offers Chinese companies and investors everything in one place: a concentration of financial
More informationPROJECT WORKOUT THE. The ultimate handbook of project and programme management ROBERT BUTTRICK. Prentice Hall FOURTH EDITION
THE PROJECT WORKOUT FOURTH EDITION The ultimate handbook of project and programme management ROBERT BUTTRICK Prentice Hall FINANCIAL TIMES An imprint of Pearson Education Harlow, England London New York
More information*NOTICE * THIS APPLICATION WAS REVISED IN JULY 2016 PLEASE READ CAREFULLY -
*NOTICE * THIS APPLICATION WAS REVISED IN JULY 2016 PLEASE READ CAREFULLY - Change of Ownership License Application To Operate a Cerebral Palsy Treatment Facility Regulations affecting the application
More informationPanel 1 Canada s Investment Advantage
Panel 1 Canada s Investment Advantage Competitive Alternatives 2014 - KPMG s Guide to International Business Location Costs 8 th Chinese Enterprises Outbound Investment Conference April 2014 Jamie Samograd
More informationEXECUTIVE ORDER 12333: UNITED STATES INTELLIGENCE ACTIVITIES
EXECUTIVE ORDER 12333: UNITED STATES INTELLIGENCE ACTIVITIES (Federal Register Vol. 40, No. 235 (December 8, 1981), amended by EO 13284 (2003), EO 13355 (2004), and EO 13470 (2008)) PREAMBLE Timely, accurate,
More informationBRISTOL-MYERS SQUIBB DATA SHARING INDEPENDENT REVIEW COMMITTEE (IRC) CHARTER
BRISTOL-MYERS SQUIBB DATA SHARING INDEPENDENT REVIEW COMMITTEE (IRC) CHARTER Charter Effective Date: October 13, 2017 Release v2.0 Page 1 of 6 Introduction This Charter describes the roles and responsibilities
More informationKaren W. Dyer MT(ASCP), DLM Director, Division of Laboratory Services Centers for Medicare & Medicaid Services CLIA
Karen W. Dyer MT(ASCP), DLM Director, Division of Laboratory Services Centers for Medicare & Medicaid Services Objectives Basics Certificate of Waiver (CoW) laboratories Triagency responsibilities FDA
More informationNOT-FOR-PROFIT INSIDER
NOT-FOR-PROFIT INSIDER VOLUME 9 :: ISSUE 3 In This Issue: Streamlining OMB Guidance For Federal Funding Of Nonprofit Organizations New 1023-EZ Makes Applying For 501(C)(3) Tax-Exempt Status Easier Identifying
More informationioutpatient SRP The Patient-focused Service for Outpatients
Solution Ready Platform ioutpatient SRP The -focused for Outpatients Integrating Outpatient s by Intelligent System Facilitating the of Outpatient Clinic Achieving Better Experiences iward Solution Website
More informationUniversity of San Francisco Office of Contracts and Grants Subaward Policy and Procedures
Summary 1. Subaward Definitions A. Subaward B. Subrecipient University of San Francisco Office of Contracts and Grants Subaward Policy and Procedures C. Office of Contracts and Grants (OCG) 2. Distinguishing
More informationPathways to Progress. Global Youth Survey 2017: Economic Prospects & Expectations
Pathways to Progress Global Youth Survey 2017: Economic Prospects & Expectations Presented by Dorothy Stuehmke Senior Program Officer, Citi Foundation Global Pathways to Progress Commitment Citi Foundation
More informationDEPARTMENT OF ENVIRONMENTAL PROTECTION Policy Office. Policy for Development and Publication of Technical Guidance
DEPARTMENT OF ENVIRONMENTAL PROTECTION Policy Office DOCUMENT NUMBER 012-0900-001 TITLE: EFFECTIVE DATE: AUTHORITY: POLICY: PURPOSE: APPLICABILITY: DISCLAIMER: Policy for Development and Publication of
More informationSourcing Solutions: Challenges & Opportunities in Global Nearshoring
September 2015 Sourcing Solutions: Challenges & Opportunities in Global Nearshoring Enterprise Improvement Financial Advisory Information Management Leadership & Organizational Effectiveness Turnaround
More informationISDN. Over the past few years, the Office of the Inspector General. Assisting Network Members Develop and Implement Corporate Compliance Programs
Information Bulletin #7 ISDN National Association of Community Health Centers, Inc. INTEGRATED SERVICES DELIVERY NETWORKS SERIES For more information contact Jacqueline C. Leifer, Esq. or Marcie H. Zakheim,
More informationGAO. United States General Accounting Office Testimony. For Release On Delivery Expected on Wednesday March 21, 1990
GAO United States General Accounting Office Testimony For Release On Delivery Expected on Wednesday March 21, 1990 DEFENSE INDUSTRIAL SECURITY Special Security 4greements Permit Foreign-owned U.S. Firms
More information